Cost Study of Linezolid Versus Vancomycin Among Previously Hospitalized Patients
Status:
Completed
Trial end date:
2012-05-01
Target enrollment:
Participant gender:
Summary
This is a retrospective, observational, non-interventional drug study using de-identified
data from two administrative claims datasets. The study design and analysis will reflect the
perspective of the commercially insured. The objectives of this study are twofold:
1. To compare the rates of re-hospitalization among patients treated with either linezolid
orally or IV, or vancomycin IV for complicated skin and skin structure infections
(cSSSI) or pneumonia hospitalization.
2. To compare the total direct medical costs of patients treated with linezolid orally or
IV, or vancomycin IV for cSSSI or pneumonia hospitalization.
Details
Lead Sponsor:
Pfizer
Collaborators:
Lodise & Lodise, LLC University of Maryland University of Maryland, College Park